With Revlimid sales down, BMS slashes 2023 revenue projection
Jul 27, 2023 · BMS sliced its 2023 sales projection for blood cancer drug Revlimid by a whopping $1 billion and cut its overall revenue projection. Instead of a previous forecast of a 2% revenue increase for...
Bristol Myers Squibb's Revlimid finally faces competition in the …
Mar 7, 2022 · Sales of Bristol Myers Squibb’s Revlimid crescendoed at $12.8 billion in 2021, the final year of exclusivity for the multiple myeloma treatment. But now, BMS can no longer hold off generic...
Focus on new products at pharma companies as generic Revlimid ...
1 day ago · The NSE Pharma index outperformed the benchmark Nifty 50 index by a wide margin in 2024 as drug companies benefited from a benign pricing environment in the US and earnings upgrades. For several ...
BMS reports 2% revenue loss in 2023 after Revlimid generics hurt …
Feb 2, 2024 · The company saw a decrease in sales of Revlimid (lenalidomide) following the entry of generic versions after its patent loss in 2022. Revlimid generated $6bn in 2023, compared to $12.9bn in 2021 before the loss.
BMS feels the pain of Revlimid erosion, cutting forecasts
Jul 28, 2023 · The hardest hit in its second-quarter results update was to blood cancer therapy Revlimid (lenalidomide), which is now expected to make around $5.5 billion this year – fully $1 billion less than...
Dr Reddy's surges 4% on Nuvama upgrade to 'buy ... - Moneycontrol
2 days ago · Nuvama expect Dr Reddy's new launches--Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026. Moneycontrol News January 08, 2025 / 09 ...
Amid generic attack, BMS's Revlimid shows it can take a punch
Jul 27, 2022 · For now, BMS is sticking with its guidance for 2022 Revlimid sales to fall between $9 and $9.5 billion. Sales of the drug crescendoed at $12.8 billion last year. In fact, Revlimid's...
Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma
3 days ago · “These FDA approvals are good news for patients with multiple myeloma, who may now benefit from these more effective initial treatments,” said Elizabeth Hill, M.D., a multiple myeloma specialist in NCI’s Center for Cancer Research, who was not involved in either trial. ... Lenalidomide and dexamethasone are taken as pills and bortezomib ...
What’s after Revlimid for Dr Reddy’s, Cipla, and Sun Pharma?
Feb 20, 2024 · Frontline pharmaceutical majors Cipla, Sun Pharma and Dr Reddy’s have had bumper earnings over the last few quarters, thanks to the high-margin blockbuster cancer drug Revlimid.
Bristol Myers profit beats estimates on resilient Revlimid sales
Jul 27, 2022 · Bristol Myers Squibb Co on Wednesday reported bigger second-quarter profit than expected as sales of its blockbuster cancer drug Revlimid did not drop as steeply as feared despite competition...
- Some results have been removed